Immunovant (IMVT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Immunovant (IMVT)
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Key Insights
Critical company metrics and information
Share Price
$28.52Market Cap
$4.19 BillionTotal Outstanding Shares
146.79 Million SharesTotal Employees
207Dividend
No dividendIPO Date
June 21, 2019SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.immunovant.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $200.50 Million |
| Net Cash Flow From Investing Activities, Continuing | $659000.00 |
| Net Cash Flow From Investing Activities | $659000.00 |
| Net Cash Flow | $203.01 Million |
| Net Cash Flow From Operating Activities | $-271.64 Million |
| Exchange Gains/Losses | $2.51 Million |
| Net Cash Flow From Operating Activities, Continuing | $-271.64 Million |
| Net Cash Flow From Financing Activities, Continuing | $472.81 Million |
| Net Cash Flow From Financing Activities | $472.81 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Net Income/Loss Available To Common Stockholders, Basic | $-323.01 Million |
| Basic Average Shares | $293.36 Million |
| Income/Loss From Continuing Operations After Tax | $-323.01 Million |
| Diluted Average Shares | $293.36 Million |
| Income Tax Expense/Benefit | $279000.00 |
| Net Income/Loss Attributable To Parent | $-323.01 Million |
| Basic Earnings Per Share | $2.22 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Operating Expenses | $352.46 Million |
| Income/Loss From Continuing Operations Before Tax | $-322.73 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Diluted Earnings Per Share | $2.22 |
| Net Income/Loss | $-323.01 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Assets | $507.37 Million |
| Noncurrent Assets | $8.34 Million |
| Other Current Assets | $474.82 Million |
| Liabilities And Equity | $515.71 Million |
| Liabilities | $66.65 Million |
| Accounts Payable | $20.73 Million |
| Assets | $515.71 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Noncurrent Liabilities | $0.00 |
| Prepaid Expenses | $32.55 Million |
| Current Liabilities | $66.65 Million |
| Other Current Liabilities | $45.93 Million |
| Equity Attributable To Parent | $449.05 Million |
| Equity | $449.05 Million |
| Other Non-current Assets | $7.66 Million |
| Fixed Assets | $671000.00 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.